Abstract
Several medications have been implicated in drug-induced pigmentation, with evidence for the association primarily derived from case reports. The incidence rates of drug-induced pigmentation are difficult to assess and diagnosis is often complicated by the delayed onset of pigmentation and co-existing polypharmacy. Therefore, a thorough medical history, a review of current and previous medications and a complete skin examination are necessary, with subsequent discontinuation of the suspected causative agent to resolve symptoms.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nahhas AF, Braunberger TL, Hamzavi IH. An update on drug-induced pigmentation. Am J Clin Dermatol. 2019;20(1):75–96.
Armenta AM, Henkel ED, Ahmed AM. Pigmentation disorders in the elderly. Drugs Aging. 2019;36(3):235–45.
Dereure O. Drug-induced skin pigmentation: epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253–62.
Dai J, Belum VR, Wu S, et al. Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(5):902-10.e2.
Rajpar SF, Marsden JR. Imiquimod in the treatment of lentigo maligna. Br J Dermatol. 2006;155(4):653–6.
Lee HY, Lim KH, Ryu Y, et al. Bleomycin-induced flagellate erythema: a case report and review of the literature. Oncol Lett. 2014;8:933–5.
Kumar B, Saraswat A, Kaur I. Mucocutaneous adverse effects of hydroxyurea: a prospective study of 30 psoriasis patients. Clin Exp Dermatol. 2002;27(1):8–13.
Tsao AS, Kantarjian H, Cortes J, et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98(11):2483–7.
Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48(2):201–6.
Brazzelli V, Prestinari F, Barbagallo T, et al. A long-term time course of colorimetric assessment of the effects of imatinib mesylate on skin pigmentation: a study of five patients. J Eur Acad Dermatol Venereol. 2007;21(3):384–7.
Drummond A, Micallef-Eynaud P, Douglas WS, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol. 2003;120(5):911–3.
Leong KW, Lee TC, Goh AS. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2004;100(11):2486–7.
Rappersberger K, Honigsmann H, Ortel B, et al. Photosensitivity and hyperpigmentation in amiodarone-treated patients: incidence, time course, and recovery. J Investig Dermatol. 1989;93(2):201–9.
Skare T, Ribeiro CF, Souza FH, et al. Antimalarial cutaneous side effects: a study in 209 users. Cutan Ocul Toxicol. 2011;30(1):45–9.
Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015;60(9):1361–7.
Pitt F. Tuberculosis, prevention and therapy. In: Hook EWMG, Gwatney JM, et al., editors. Current concepts of infection sdisease. New York: Wiley; 1977. p. 181–94.
McGrae JD Jr, Zelickson AS. Skin pigmentation secondary to minocycline therapy. Arch Dermatol. 1980;116(11):1262–5.
Simons JJ, Morales A. Minocycline and generalized cutaneous pigmentation. J Am Acad Dermatol. 1980;3(3):244–7.
Patel K, Cheshire D, Vance A. Oral and systemic effects of prolonged minocycline therapy. Br Dent J. 1998;185(11–12):560–2.
Eisen D, Hakim MD. Minocycline-induced pigmentation: incidence, prevention and management. Drug Saf. 1998;18(6):431–40.
Fraunfelder FT, Randall JA. Minocycline-induced scleral pigmentation. Ophthalmology. 1997;104(6):936–8.
Pepine M, Flowers FP, Ramos-Caro FA. Extensive cutaneous hyperpigmentation caused by minocycline. J Am Acad Dermatol. 1993;28(2 Pt 2):292–5.
Mondou E, Hinkle J, Shaw A, et al. Incidence of skin discoloration across phase 3 clinical trials of emtricitabine (FTC) in adults. In: International AIDS conference, Bangkok; 2004.
Shirasaka T, Tadokoro T, Yamamoto Y, et al. Investigation of emtricitabine-associated skin pigmentation and safety in HIV-1-infected Japanese patients. J Infect Chemother. 2011;17(5):602–8.
Sharpe ED, Reynolds AC, Skuta GL, et al. The clinical impact and incidence of periocular pigmentation associated with either latanoprost or bimatoprost therapy. Curr Eye Res. 2007;32(12):1037–43.
Resnik S. Melasma induced by oral contraceptive drugs. JAMA. 1967;199(9):601–5.
Author information
Authors and Affiliations
Consortia
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Conflict of interest
The article was adapted from the American Journal of Clinical Dermatology 2019; 20(1):75–96 [1] by employees of Adis International Ltd./Springer Nature, who are responsible for the article content and declare no conflicts of interest.
Rights and permissions
About this article
Cite this article
Adis Medical Writers. Examine the skin and thoroughly review medical/medication history when considering a diagnosis of drug-induced pigmentation. Drugs Ther Perspect 35, 418–423 (2019). https://doi.org/10.1007/s40267-019-00659-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-019-00659-z